GSK has reported a 7% increase in full-year revenue for 2024, reaching £31.4 billion ($39.3 billion), slightly surpassing market expectations. The fourth quarter contributed £8.1 billion, a 4% rise ...
“We really became impressed with what IDRx had achieved,” GSK Chief Commercial Officer Luke Miels told Fierce Biotech in an interview ahead of the J.P. Morgan Healthcare Conference.
chief commercial officer at GSK, said in Monday’s announcement. Just last August, IDRx raised a $120 million Series B financing led by RA Capital Management, Commodore Capital and Blackstone ...
In a statement, GSK chief commercial officer Luke Miels said that the drug "complements [the company's] growing portfolio in gastrointestinal cancers," which also includes anti-PD-1 antibody ...
Luke Miels, GSK’s chief commercial officer, said: “This acquisition is consistent with our approach of acquiring assets that address validated targets and where there is clear unmet medical ...
Shares of GSK plc (NYSE:GSK – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat reports. Six ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback